Global Alzheimer's trial will study Roche, Lilly drugs

10/10/2012 | Reuters

Experimental Alzheimer's drugs from Roche Holding and Eli Lilly and Co. will be studied in a global trial of 160 patients with genetic indicators that they are prone to the disease. The study, set to begin next year, will include Roche's gantenerumab and Lilly's solanezumab, and a beta-secretase inhibitor from Lilly could be added.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC